Remission of psoriatic lesions with muromonab-CD3 (Orthoclone OKT3) treatment
1989; Elsevier BV; Volume: 20; Issue: 6 Linguagem: Inglês
10.1016/s0190-9622(89)80200-2
ISSN1097-6787
AutoresBrian G. Weinshenker, Brenda H. Bass, George C. Ebers, George P. Rice,
Tópico(s)Dermatology and Skin Diseases
ResumoA 39-year-old woman received a 10-day treatment with muromonab-CD3 (Orthoclone OKT3) (total dose 50 mg) as part of a clinical trial designed to test its efficacy in the treatment of multiple sclerosis. The patient concomitantly received methylprednisolone (Solu-Medrol), 50 mg on the first day of treatment, and indomethacin, 50 mg, three times daily throughout the 10-day course. She had had psoriasis vulgaris for 18 years, which was largely confined to extensor surfaces of her arms and legs. She had received intermittent treatment with topical coal tar preparations in the past without benefit. The condition
Referência(s)